RU2018139339A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018139339A3 RU2018139339A3 RU2018139339A RU2018139339A RU2018139339A3 RU 2018139339 A3 RU2018139339 A3 RU 2018139339A3 RU 2018139339 A RU2018139339 A RU 2018139339A RU 2018139339 A RU2018139339 A RU 2018139339A RU 2018139339 A3 RU2018139339 A3 RU 2018139339A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201607046 | 2016-04-22 | ||
| GB1607046.8 | 2016-04-22 | ||
| PCT/EP2017/059656 WO2017182672A1 (en) | 2016-04-22 | 2017-04-24 | Novel bispecific polypeptides against cd137 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018139339A RU2018139339A (ru) | 2020-05-22 |
| RU2018139339A3 true RU2018139339A3 (ru) | 2020-09-28 |
Family
ID=58609424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018139339A RU2018139339A (ru) | 2016-04-22 | 2017-04-24 | Новые биспецифические полипептиды против cd137 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190169308A1 (ru) |
| EP (1) | EP3445788B1 (ru) |
| JP (2) | JP2019523630A (ru) |
| KR (1) | KR102426765B1 (ru) |
| CN (1) | CN109195994A (ru) |
| AU (1) | AU2017252233A1 (ru) |
| BR (1) | BR112018071612A2 (ru) |
| CA (1) | CA3021618A1 (ru) |
| DK (1) | DK3445788T3 (ru) |
| ES (1) | ES2910365T3 (ru) |
| IL (1) | IL262482A (ru) |
| MX (1) | MX2018012897A (ru) |
| RU (1) | RU2018139339A (ru) |
| WO (1) | WO2017182672A1 (ru) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3025345A1 (en) | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| TW201803906A (zh) | 2016-06-20 | 2018-02-01 | Ｆ星德爾塔有限公司 | 結合物件(二) |
| RU2018142573A (ru) | 2016-06-20 | 2020-07-21 | Ф-Стар Бета Лимитед | Партнеры по связыванию lag-3 |
| CA3030636A1 (en) | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| MA46278A (fr) * | 2016-09-23 | 2019-07-31 | Merus Nv | Molécules de liaison qui modulent une activité biologique exprimée par une cellule |
| KR20240165484A (ko) | 2017-04-11 | 2024-11-22 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법 |
| US11242385B2 (en) | 2017-04-13 | 2022-02-08 | Agenus Inc. | Anti-CD137 antibodies and methods of use thereof |
| SG11202000503QA (en) | 2017-07-20 | 2020-02-27 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| ES2926195T3 (es) | 2017-08-04 | 2022-10-24 | Bicycletx Ltd | Ligandos peptídicos bicíclicos específicos de CD137 |
| SG11202003912RA (en) * | 2017-11-13 | 2020-05-28 | Crescendo Biologics Ltd | Single Domain Antibodies that Bind to CD137 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP7489316B2 (ja) | 2017-12-19 | 2024-05-23 | エフ－スター セラピューティクス リミテッド | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 |
| CN109970865B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd137双向激活共刺激分子受体及其用途 |
| CN111971298A (zh) | 2018-03-12 | 2020-11-20 | 健玛保 | 抗体 |
| AU2019247795B2 (en) * | 2018-04-04 | 2024-08-15 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| WO2019232323A1 (en) * | 2018-05-31 | 2019-12-05 | Board Of Regents, The University Of Texas System | Bi-specific antibodies and use thereof |
| EP3802601A1 (en) * | 2018-06-06 | 2021-04-14 | Leadartis, S.L. | Trimeric polypeptide complexes and uses thereof |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811450D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
| GB201811415D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN112996809A (zh) * | 2018-10-10 | 2021-06-18 | 酵活有限公司 | 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途 |
| WO2020076992A1 (en) * | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
| WO2020083277A1 (zh) * | 2018-10-22 | 2020-04-30 | 上海一宸医药科技有限公司 | 一种双特异性抗体 |
| SG11202105152YA (en) | 2018-11-30 | 2021-06-29 | Abl Bio Inc | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
| GB201820556D0 (en) * | 2018-12-17 | 2019-01-30 | Alligator Bioscience Ab | Novel polypeptides |
| US20220064325A1 (en) * | 2018-12-17 | 2022-03-03 | Alligator Bioscience Ab | Novel polypeptides |
| WO2020127376A2 (en) * | 2018-12-17 | 2020-06-25 | Alligator Bioscience Ab | Novel polypeptides |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| GB201905100D0 (en) * | 2019-04-10 | 2019-05-22 | Antibody Innovation Ltd | Polypeptides and methods of use |
| JP2022532134A (ja) | 2019-05-09 | 2022-07-13 | バイスクルテクス・リミテッド | Ｏｘ４０に特異的な二環式ペプチドリガンド |
| EP4004053A4 (en) * | 2019-07-26 | 2023-10-18 | ABL Bio, Inc. | BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND ITS USE |
| AU2020320233A1 (en) | 2019-07-26 | 2022-02-17 | Yuhan Corporation | Anti-HER2/anti-4-1BB bispecific antibody and use thereof |
| TWI862640B (zh) * | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN112592404B (zh) * | 2019-09-20 | 2023-07-25 | 上海交通大学医学院 | 抗体活性改造及其筛选方法 |
| EP4464721A3 (en) * | 2019-10-03 | 2025-03-12 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
| EP3816185A1 (en) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| WO2021101346A1 (en) * | 2019-11-21 | 2021-05-27 | Dong-A St Co., Ltd. | Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof |
| WO2021137230A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
| WO2021137231A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
| KR20220124718A (ko) | 2020-01-07 | 2022-09-14 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체 |
| AU2021228078A1 (en) * | 2020-02-28 | 2022-09-22 | Shanghai Henlius Biotech, Inc. | Anti-CD137 constructs, multispecific antibody and uses thereof |
| US20230265202A1 (en) * | 2020-04-15 | 2023-08-24 | Zymeworks Inc. | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof |
| KR20230012559A (ko) | 2020-05-19 | 2023-01-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 결합 분자 |
| KR20230013125A (ko) * | 2020-06-30 | 2023-01-26 | 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 | 4-1bb 결합 단백질 및 이의 용도 |
| KR20230042524A (ko) * | 2020-08-07 | 2023-03-28 | 주식회사 유틸렉스 | 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도 |
| EP4240762A1 (en) * | 2020-11-03 | 2023-09-13 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
| CN116745309A (zh) * | 2021-01-25 | 2023-09-12 | 柳韩洋行 | 用于纯化抗-4-1bb/抗-her2双特异性抗体的方法 |
| CA3228414A1 (en) * | 2021-09-02 | 2023-03-09 | Anthony DANIYAN | Anti-cd33 antibodies and uses thereof |
| CN118510804A (zh) * | 2021-10-12 | 2024-08-16 | 乐普创一生物科技（上海）有限公司 | 4-1bb单域抗体 |
| WO2023174521A1 (en) * | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| WO2024051752A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Multispecific constructs and uses thereof |
| CN119790076A (zh) * | 2022-09-22 | 2025-04-08 | 成都盛世君联生物技术有限公司 | 一种抗4-1bb纳米抗体及其制备和应用 |
| AU2023365438A1 (en) * | 2022-10-19 | 2025-04-17 | Astellas Pharma Inc. | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment |
| KR20240095012A (ko) * | 2022-11-29 | 2024-06-25 | (주) 테라베스트 | Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도 |
| WO2024143643A1 (ko) * | 2022-12-30 | 2024-07-04 | 앱클론(주) | Cd137에 특이적으로 결합하는 어피바디 및 이의 용도 |
| WO2025056180A1 (en) * | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| DE60040555D1 (de) * | 1999-11-18 | 2008-11-27 | Oxford Biomedica Ltd | Küle |
| CN100490895C (zh) * | 2000-02-01 | 2009-05-27 | 泛遗传学公司 | 结合cd40的apc激活分子 |
| LT2857516T (lt) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalentiniai antikūnai ir jų panaudojimas |
| US20060088522A1 (en) | 2004-09-10 | 2006-04-27 | Wyeth | Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| DK2663580T3 (en) | 2011-01-10 | 2017-03-13 | Ct Atlantic Ltd | COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES |
| US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
| EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2013041687A1 (en) * | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CA2943943C (en) * | 2014-04-07 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| US20150307620A1 (en) * | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| CN112546230A (zh) * | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CA3224830A1 (en) * | 2015-01-08 | 2016-07-14 | Biontech Ag | Agonistic tnf receptor binding agents |
| EP3245227A4 (en) * | 2015-01-14 | 2018-07-25 | Compass Therapeutics LLC | Multispecific immunomodulatory antigen-binding constructs |
| EP3988577A1 (en) * | 2015-05-21 | 2022-04-27 | Alligator Bioscience AB | Anti-cd137 antibodies |
| BR112019017628A2 (pt) * | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| SG11202000503QA (en) | 2017-07-20 | 2020-02-27 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
-
2017
- 2017-04-24 RU RU2018139339A patent/RU2018139339A/ru unknown
- 2017-04-24 ES ES17718928T patent/ES2910365T3/es active Active
- 2017-04-24 US US16/094,127 patent/US20190169308A1/en not_active Abandoned
- 2017-04-24 CA CA3021618A patent/CA3021618A1/en active Pending
- 2017-04-24 BR BR112018071612-0A patent/BR112018071612A2/pt not_active IP Right Cessation
- 2017-04-24 DK DK17718928.9T patent/DK3445788T3/da active
- 2017-04-24 KR KR1020187030680A patent/KR102426765B1/ko active Active
- 2017-04-24 MX MX2018012897A patent/MX2018012897A/es unknown
- 2017-04-24 CN CN201780025116.2A patent/CN109195994A/zh active Pending
- 2017-04-24 AU AU2017252233A patent/AU2017252233A1/en not_active Abandoned
- 2017-04-24 EP EP17718928.9A patent/EP3445788B1/en active Active
- 2017-04-24 JP JP2018555198A patent/JP2019523630A/ja active Pending
- 2017-04-24 WO PCT/EP2017/059656 patent/WO2017182672A1/en active Application Filing
-
2018
- 2018-10-21 IL IL262482A patent/IL262482A/en unknown
-
2021
- 2021-09-23 US US17/482,708 patent/US12173082B2/en active Active
- 2021-11-26 JP JP2021192091A patent/JP2022058338A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022058338A (ja) | 2022-04-12 |
| JP2019523630A (ja) | 2019-08-29 |
| KR20180135454A (ko) | 2018-12-20 |
| EP3445788B1 (en) | 2022-01-19 |
| BR112018071612A2 (pt) | 2019-02-19 |
| ES2910365T3 (es) | 2022-05-12 |
| CA3021618A1 (en) | 2017-10-26 |
| MX2018012897A (es) | 2019-01-17 |
| CN109195994A (zh) | 2019-01-11 |
| AU2017252233A1 (en) | 2018-11-15 |
| DK3445788T3 (en) | 2022-04-11 |
| KR102426765B1 (ko) | 2022-07-29 |
| WO2017182672A1 (en) | 2017-10-26 |
| EP3445788A1 (en) | 2019-02-27 |
| IL262482A (en) | 2018-12-31 |
| US20220213213A1 (en) | 2022-07-07 |
| US20190169308A1 (en) | 2019-06-06 |
| US12173082B2 (en) | 2024-12-24 |
| RU2018139339A (ru) | 2020-05-22 |